https://www.selleckchem.com/pr....oducts/Azacitidine(V
001). The radiomics signature exhibited favorable discrimination between the indolent and aggressive PCa groups in the training set (AUC 0.853, 95% CI 0.766 to 0.941) and validation set (AUC 0.901, 95% CI 0.793 to 1.00. The decision curve analysis showed that a greater net benefit would be obtained when the threshold probability ranged from 20 to 90%. The multiparametric MRI-based radiomics signature can potentially serve as a noninvasive tool for distinguishing between indolent and aggressive PCa prior to therapy. The mul